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Background: Alternative splicing is often subjected to complex regulatory control that involves many protein
factors and cis-acting RNA sequence elements. One major challenge is to identify all of the protein players and
define how they control alternative expression of a particular exon in a combinatorial manner. The Muscleblind-like
(MBNL) and CUG-BP and ELAV-Like family (CELF) proteins are splicing regulatory proteins, which function as
antagonists in the regulation of several alternative exons. Currently only a limited number of common targets of
MBNL and CELF are known that are antagonistically regulated by these two groups of proteins.
Results: Recently, we identified neurofibromatosis type 1 (NF1) exon 23a as a novel target of negative regulation
by CELF proteins. Here we report that MBNL family members are positive regulators of this exon. Overexpression of
MBNL proteins promote exon 23a inclusion in a low MBNL-expressing cell line, and simultaneous siRNA-mediated
knockdown of MBNL1 and MBNL2 family members in a high MBNL-expressing cell line promotes exon 23a
skipping. Importantly, these two groups of proteins antagonize each other in regulating inclusion of exon 23a.
Furthermore, we analyzed the binding sites of these proteins in the intronic sequences upstream of exon 23a by
UV cross-linking assays. We show that in vitro, in addition to the previously identified preferred binding sequence
UGCUGU, the MBNL proteins need the neighboring sequences for optimal binding.
Conclusion: This study along with our previous work that demonstrated roles for Hu, CELF, and TIA-1 and TIAR
proteins in the regulation of NF1 exon 23a establish that this exon is under tight, complex control.
Keywords: Muscleblind-like (MBNL) proteins, CUG-BP and ELAV-like family (CELF proteins), Alternative splicing,
Neurofibromatosis type I (NF1), Splicing regulation, Complex controlBackground
Alternative splicing allows more than one protein prod-
uct to be generated from a single gene by selectively in-
cluding or excluding particular exons in the mature
mRNA transcripts. This is a prevalent mechanism of
gene regulation with as many as 94% of human genes
predicted to undergo the process [1,2]. Alternative spli-
cing is important in development, in the establishment
of tissue specificity and sex differences, and in human
disease etiology and progression [3-7].* Correspondence: hua.lou@case.edu
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reproduction in any medium, provided the orAlternative splicing is a tightly regulated process
involving cis-sequences on the RNA and protein factors
that can either promote the inclusion or the skipping of
a particular alternative exon in the mature mRNA.
Regulatory mechanisms that govern alternative splicing
have been extensively studied, and a number of splicing
regulatory proteins have been identified and the cis-
sequences to which they bind have been characterized
[5,6,8-15]. More recently other means of splicing regulation
have been demonstrated including chromatin remodeling
and involvement of the C-terminal domain of RNA
Polymerase II as a staging platform for splicing factors
during coupled transcription and splicing [16-18].
Two families of well-characterized splicing regulators
are the CUG-binding protein (CUG-BP) and embryonicl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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the Muscleblind-like (MBNL) proteins. CELF and MBNL
proteins play important roles in the human neuromus-
cular disease myotonic dystrophy (DM), where their
mis-regulation causes alterations in splicing patterns of
their target mRNAs. In DM1, CELF protein activity is
up regulated, while MBNL protein activity is lost.
Interestingly, while these two groups of RNA-binding
proteins are known to have distinct mRNA targets, it
is also well established that they function antagonistically
in the regulation of several alternative exons. The well-
characterized common pre-mRNA targets that are antag-
onistically regulated by CELF and MBNL proteins include
cardiac troponin T (cTNT) exon 5, insulin receptor (IR)
exon 11, chloride channel 1 (CLCN1) exon 7a, and tau
exon 6 [19-21]. Alternative splicing of these exons is mis-
regulated in myotonic dystrophy. In these well-studied
targets, CELF and MBNL proteins bind to distinct cis-
elements. For example, Ho and colleagues utilized cTNT
exon 5 minigene reporters in which the potential CELF
or MBNL motifs were disrupted to demonstrate that the
loss of one family’s binding site does not impact regula-
tion of cTNT exon 5 by the other protein family [20]. In
the case of cTNT exon 5, it has been established that
MBNL proteins compete with the essential basal splicing
factor U2AF65 for binding of the 3’ end of the cTNT in-
tron, and when MBNL prevails it is bound to and pos-
sibly stabilizes a secondary structure that prevents
U2AF65 binding [22]. An additional six antagonistically
regulated targets were identified in a microarray analysis
in the developing heart by Kalsotra and colleagues [23].
In DM1 disease, the antagonistically regulated CELF and
MBNL protein splicing targets are especially adversely
affected, since MBNL function is lost and CELF function
is dramatically increased. For this reason, it is important
to identify additional antagonistically regulated targets of
these two families of regulatory proteins.
Our laboratory has identified one of the alternative
exons of the neurofibromatosis type I (NF1) pre-mRNA,
exon 23a, as a target of complex splicing regulation.
Exon 23a is a particularly attractive exon to study be-
cause its coded amino acid sequences are located within
the best-characterized domain of the NF1 protein known
as the GTPase activating protein-related domain (GRD).
The GRD allows the NF1 protein to mediate the conversion
of active guanosine-triphosphate bound Ras (Ras-GTP) to
inactive guanosine-diphosphate bound Ras (Ras-GDP)
(reviewed by [24]). Interestingly, the type II isoform which
includes exon 23a is ten times weaker at regulating the con-
version of Ras-GTP to Ras-GDP than the type I isoform in
which exon 23a is skipped [25,26]. Previously, our labora-
tory has shown that this exon is regulated by at least three
different splicing factor protein families: CELF, Hu, and
TIA-1 and TIAR [27-29].Recently we have identified two potential MBNL binding
sites, both containing UGCUGU, in the intronic region
upstream of exon 23a. In this report we provide evi-
dence to support that the MBNL family of splicing
regulators act as positive regulators of NF1 exon 23a
inclusion. MBNL1, 2, and 3 all promote exon 23a inclu-
sion when over-expressed in a low MBNL protein-expres-
sing, neuron-like cell line along with an NF1 minigene
reporter. Simultaneous siRNA-mediated knockdown of
endogenous MBNL1 and MBNL2 proteins in HeLa cells
promotes NF1 exon 23a skipping. Our UV cross-linking
assays demonstrate that recombinant MBNL1 binds to
wild-type RNA oligonucleotides, but not to mutant
RNA oligonucleotides in which the potential MBNL
sites have been disrupted by mutation to AUAAUA.
We show in cells that the relative levels of MBNL and
CELF proteins govern whether or not exon 23a will be
included, thus showing that CELF and MBNL proteins
antagonistically regulate NF1 exon 23a. These results
add NF1 exon 23a to a short list of alternative exons
that are under complex control by these two families of
RNA-binding proteins.
Results
Endogenous NF1 exon 23a inclusion patterns differ in
two cell models
Previous studies have shown that NF1 exon 23a is differ-
entially spliced. This exon is predominantly included in
most tissues, but it is mostly skipped in neurons [30,31].
To study the regulatory mechanisms by which this exon
is expressed, we took advantage of two different cell
model systems, HeLa cells and CA77 cells [27,29]. HeLa
cells mimic the high inclusion level of NF1 exon 23a
that is seen in most tissues, while CA77 cells are used to
model the neuronal phenotype where NF1 exon 23a in-
clusion is low (Figure 1A). We use semi-quantitative,
radioactive RT-PCR with primers that anneal to exons
23 and 24 to assess the inclusion pattern differences be-
tween the cells as documented previously [27]. We have
shown that these cells are appropriate experimental
models for examining exon 23a inclusion [27,29]. Note
that according to the NF1 legacy nomenclature, exon 23
is also known as exon 23-II.
The intronic sequence upstream of NF1 exon 23a is
UG-rich and contains two potential MBNL protein binding
sites
We previously demonstrated that the CELF proteins act
as negative regulators of NF1 exon 23a inclusion, and
that these proteins bind to the UG-rich sequences
located in the intronic region upstream of exon 23a
(Figure 1B and [27]). Upon closer examination of the in-
tronic sequence upstream of exon 23a, we identified two
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Figure 1 Endogenous NF1 exon 23a inclusion patterns and UG-rich upstream intronic sequence. (A) A representation of endogenous NF1
exon 23a inclusion patterns. Exon 23a is predominantly included in most tissues, while it is predominantly skipped in neurons. Arrows represent
RT-PCR oligonucleotides designed to analyze NF1 exon 23a splicing patterns. (B) The intronic region upstream of NF1 exon 23a is UG-rich and
harbors two potential Muscleblind-like (MBNL) protein binding motifs (UGCUGU) which are underlined.
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Figure 2 Over-expression of the MBNL protein family members promotes NF1 exon 23a inclusion. (A) Schematic representation of the
HMT-NF1 863/499 minigene reporter construct. (B) Co-transfection of CA77 cells with the HMT-NF1 863/499 reporter (0.5 μg) and human MBNL
(2 μg) protein expression plasmids. Total RNA was isolated from the transfected cells and semi-quantitative RT-PCR was performed using the
primers denoted by arrows in (A). The percentage of NF1 exon 23a inclusion is displayed in the bar graph. Error bars indicate standard deviations
and n=3. Total CA77 protein lysate was collected from transfected cells and Western blot analysis was performed using anti-Xpress antibody.
Anti-U1 70K was utilized as a loading control.
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presence of the potential MBNL binding sites and the
fact that CELF and MBNL are known to act as antago-
nists in the splicing regulation of several well-studied
pre-mRNA targets led us to hypothesize that the MBNL
proteins might also regulate NF1 exon 23a inclusion.
Since the CELF proteins are confirmed negative regula-
tors of exon 23a inclusion, we hypothesized that the
MBNL family members could act as positive regulators.
Given that currently all of the known common targets of
MBNL and CELF proteins are regulated antagonistically
by these proteins, we hypothesized that these protein
families would also function antagonistically in the NF1
exon 23a system.
Over-expression of MBNL family members in CA77 cells
promotes NF1 exon 23a inclusion
To test the hypothesis that MBNL proteins regulate NF1
exon 23a inclusion, we performed co-transfection
experiments in which individual human MBNL proteins
were over-expressed along with an NF1 minigene re-
porter construct in CA77 cells, a low MBNL expressing
cell line. The NF1 minigene reporter was created by
inserting the NF1 exon 23a sequence and sequences
from the flanking introns into the human metallothio-
nine II gene (Figure 2A and [27,29]). We assessed the
NF1 exon 23a inclusion pattern by semi-quantitative
RT-PCR using primers that anneal to sequences in exons
1 and 3 of the human metallothionine II gene. As
demonstrated by our previous work, this splicing re-
porter recapitulates the splicing phenotype of the en-
dogenous NF1 pre-mRNA [27,29]. The over-expressionsiRNA 
Ave % exon 23a 
inclusion  
78 76 47 
Figure 3 siRNA-mediated knockdown of endogenous MBNL proteins
either Control siRNA (300 pmoles) or MBNL1 (200 pmoles) plus MBNL2 (100
a negative control. Total RNA was isolated from the transfected cells and se
exons 23 and 24 (Figure 1A). The average percentage NF1 exon 23a inclusi
performed to determine changes in MBNL1 and MBNL2 mRNA levels uponof each of the three MBNL protein family members pro-
moted NF1 exon 23a inclusion, indicating that they all
work redundantly in this system (Figure 2B). Western
blot analysis using the protein lysates from transfected
CA77 cells and an anti-tag (Xpress) antibody was per-
formed to verify that the MBNL family members were
all expressed in CA77 cells (Figure 2B). As negative con-
trols, we transfected cells with an expression plasmid for
either Y-box protein or hnRNP L. Expression of neither
protein had an effect on the NF1 exon 23a inclusion
(data not shown). These results support our hypothesis
that the MBNL protein family members are positive reg-
ulators of NF1 exon 23a inclusion.
Knockdown of endogenous MBNL proteins promotes NF1
exon 23a skipping
To establish the importance of endogenous MBNL pro-
teins in the regulation of NF1 exon 23a inclusion, we
performed a siRNA knockdown experiment in which
both endogenous MBNL1 and MBNL2 proteins were
disrupted in HeLa cells (Figure 3). We found that knock-
down of the individual MBNL1 or MBNL2 proteins was
not sufficient to change NF1 exon 23a inclusion pat-
terns, since these proteins function redundantly in this
system (data not shown). However, when the levels of
both proteins were reduced endogenous NF1 exon 23a
inclusion was reduced from 78% to 47% (Figure 3). We
assessed MBNL1 and MBNL2 mRNA level changes,
upon siRNA knockdown, using an RT-PCR assay due to
difficulties with the commercially available MBNL2 anti-
body. As shown in Figure 3, both MBNL1 and MBNL2




promotes NF1 exon 23a skipping. Co-transfection of HeLa Cells with
pmoles) siRNAs. HeLa Cells were mock transfected with no siRNA for
mi-quantitative RT-PCR was performed using the primers designed in
on was determined from two independent experiments. RT-PCR was
siRNA knockdown with Beta Actin as a loading control.
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was used as a loading control, and there is no change in
its levels upon siRNA treatment. The relatively modest
change that we observed, upon siRNA knockdown of
MBNL1 and MBNL2, in exon 23a inclusion was
expected, since there are at least two other proteins that
function as positive regulators of NF1 exon 23a in HeLa
cells, TIA-1 and TIAR. In fact our results in this report
are similar to our previous study in which the effects of
the disruption of TIA-1 and TIAR proteins on NF1 exon
23a inclusion were assessed [29]. The loss of function
experiment supports our hypothesis that the MBNL pro-
teins are positive regulators of NF1 exon 23a inclusion.
MBNL and CELF proteins antagonize each other in cells
Given that CELF proteins are potent negative regulators
of NF1 exon 23a, we sought to understand whether the
MBNL proteins could antagonize their function in cell
lines. In order to test this idea, we over-expressed a con-
stant amount of the CELF family member, CELF3, in
HeLa cells and then co-expressed increasing amounts of
MBNL1 protein. HeLa cells were chosen for these
experiments because they are low CELF-expressing and
high MBNL-expressing cells ([27] and data not shown).
Since the transfection efficiency using HeLa cells is very
high, we were able to assess the splicing phenotype of
the endogenous NF1 pre-mRNA in these assays. Con-
sistent with our previous studies [27], CELF3 promoted
exon 23a skipping with a change from 78% inclusion in
the mock-transfected cells to 27% inclusion in the
CELF3 transfected cells (Figure 4A). Remarkably, with
the co-expression of MBNL1, we observed a return to
about 65% exon inclusion showing that MBNL1 can res-
cue the CELF over-expression phenotype in these cells
(Figure 4A). These results suggest that overall protein
levels of CELF and MBNL govern whether exon 23a will
be included in HeLa cells.
Next, we wanted to determine whether a similar effect
would be observed if MBNL1 and CELF3 were co-
expressed in CA77 cells. CA77 were used since they ex-
press low levels of MBNL1 and MBNL2 (data not
shown) and high levels of the CELF proteins [27]. CA77
cells are not efficiently transfected, so we utilized the
HMT-NF1 minigene reporter as described above for
these experiments. Over-expression of human MBNL1
changed NF1 exon 23a inclusion from a baseline of 39%
to 71% (Figure 4B, compare lanes 1 and 2). Co-
expression of human CELF3 protein with MBNL1 dra-
matically reduced the exon 23a inclusion level to 18%,
and thus rescued the MBNL1 protein effect in CA77
cells (Figure 4B, compare lanes 2 and 3). These results
demonstrate that the overall protein levels are also im-
portant in determining the expression of exon 23a in
CA77 cells.MBNL and CELF proteins bind to the wild-type NF1
pre-mRNA but not to mutant pre-mRNAs
Given that there are two UGCUGU-containing potential
MBNL binding sites located in the intronic sequence up-
stream of NF1 exon 23a, and that the MBNL proteins
function as positive regulators of exon 23a when over-
expressed in low MBNL-expressing cells, we hypothe-
sized that these proteins bind to the NF1 pre-mRNA.
We were interested in determining whether both poten-
tial MBNL binding sites are important for binding or if
one is more important than the other. We also wanted
to know whether the same sites are important for CELF
protein binding. To address these questions, we per-
formed UV cross-linking assays with either wild-type or
mutated RNA oligonucleotides which were end labeled
with 32P-ATP and incubated with recombinant MBNL
or CELF proteins. We designated the wild-type and mu-
tant RNA oligonucleotides as either upstream or down-
stream based on the location of the potential MBNL site
that they contain relative to the 3’ splice site (Figure 5A).
To mutate the potential MBNL binding sites, we substi-
tuted AUAAUA for UGCUGU (upstream mutants 1 and
2 and downstream mutant in Figure 5A), based on pre-
vious in vitro studies that have shown that this sequence
substitution abolishes MBNL protein binding [20]. We
also disrupted potential UG dinucleotides to which
CELF proteins are likely to bind in the absence or pres-
ence of UGCUGU mutation (upstream mutants 2 and 3
in Figure 5A). In these binding assays, we utilized GST
protein as a negative control, and as expected it did not
bind to any of the RNA sequences (Figure 5, panels B
and C). GST-MBNL1 binds strongly to both the up-
stream and downstream wild-type RNA oligonucleotide
sequences, but it does not bind to the RNA sequences in
which either of the UGCUGU motifs (Figure 5B up-
stream mutants 1 and 2, compare lanes 2, 4, and 6, and
downstream mutant, compare lanes 10 and 12) is
abolished. Interestingly, we observed that GST-MBNL1
could bind to upstream mutant 3, which contains one of
the proposed MBNL binding sites but lacks other poten-
tial UG dinucleotides, although this binding is greatly
reduced compared with the upstream wild-type se-
quence (Figure 5B, compare lanes 2 and 8). This result
was surprising, and it suggests that MBNL proteins
might require the upstream UG sequences in addition to
their UGCUGU binding site for optimal binding.
Overall, these results suggest that both UGCUGU se-
quence motifs are important for MBNL protein binding.
We found that GST-CELF2 binds strongly to the up-
stream wild-type sequence, as well as to the upstream
mutant 1 in which only the potential MBNL binding
motif is abolished (Figure 5C, compare lanes 2 and 4).
Interestingly, there is significant reduction in GST-
CELF2 binding for both upstream mutants 2 and 3, with
A MBNL1 
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Figure 4 MBNL and CELF proteins antagonize each other in cells. (A) Co-transfection of HeLa cells with human CELF3 (0.5 μg) and human
MBNL1 (1 μg, 2 μg, or 4 μg) protein expression plasmids. Total RNA was isolated from the transfected cells and semi-quantitative RT-PCR was
performed using the primers designed in exons 23 and 24 (Figure 1A). The percentage of NF1 exon 23a inclusion is displayed in the bar graph.
Error bars indicate standard deviations and n=3. Total protein was collected from the transfected HeLa cells and western blot analysis was
performed using anti-Xpress antibody and anti-U1 70K as a loading control. (B) Co-transfection of CA77 cells with HMT-NF1 863/499 reporter
(0.5 μg) and human MBNL1 (4 μg) and human CELF3 (1 μg) protein expression plasmids. Total RNA was isolated from the transfected cells and
semi-quantitative RT-PCR was performed with the primers designed in exons 1 and 3 of the HMT minigene reporter. The percentage of NF1 exon
23a inclusion is displayed in the bar graph. Error bars indicate standard deviations and n=4. Total protein was isolated from the transfected CA77
cells and a western blot analysis was performed using anti-Xpress antibody and anti-U1 70K as a loading control.




Figure 5 MBNL and CELF proteins bind strongly to wild-type
NF1 pre-mRNA, but not to mutant pre-mRNA. (A) Sequences of
RNA oligonucleotides. Potential MBNL sites are underlined.
Mutations are presented in italics. The nucleotide positions relative
to exon 23a are indicated. (B) End labeled RNA oligonucleotides
were incubated with either GST as a control (750 ng) or GST-MBNL1
(750 ng), and binding was detected by UV cross-linking assays. (C)
End labeled RNA oligonucleotides were incubated with either GST
(100 ng) or GST-CELF2 (100 ng), and binding was detected by UV
cross-linking assays.
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stream mutant 2 in which both the potential MBNL
binding motif and the other UG dinucleotides are chan-
ged (Figure 5C, compare lanes 2, 6, and 8). We also
observed a reduction in GST-CELF2 binding for the
downstream mutant, in which only the potential MBNL
site was abolished (Figure 5C, compare lanes 10 and 12).
These results suggest that GST-CELF2 binds optimally
when there are more UG-rich sites. Taken together, the
binding analysis indicates that the binding sites for
MBNL and CELF proteins are somewhat overlapping
in vitro.
Discussion
NF1 exon 23a is a novel target of MBNL protein family-
mediated splicing regulation
The Muscleblind-like proteins are important, well-
characterized splicing regulators [12,32]. A great deal
has been learned about the MBNL proteins based on
their involvement in the human disease myotonic dys-
trophy (DM). In order to better understand MBNL pro-
tein function, researchers have generated knockoutmouse models for MBNL1 and MBNL2 [33,34]. While
both of the models have some features of human DM,
including aberrant splicing of known MBNL target pre-
mRNAs, neither one fully recapitulates the human DM
patient phenotype. Furthermore, a recent study per-
formed using RNA isolated from the MBNL1 knockout
mouse and microarray analysis identified several add-
itional MBNL1 targets [35], but it is probable that many
more targets remain to be determined.
Our studies show that all three of the MBNL protein
family members function redundantly as positive regula-
tors of NF1 exon 23a when over-expressed in CA77 cells.
These findings are similar to a previous study done by Ho
and colleagues, in which all of the MBNL proteins were
shown to promote either exon inclusion in the case of the
human insulin receptor exon 11, or exon repression in
human and chicken cardiac troponin T when over-
expressed in cells along with minigene reporters [20].
Although all of the family members function redun-
dantly in the transfection experiments, MBNL3 might
not have a significant role physiologically in the regula-
tion of this alternative splicing event since its expression
profile is not as extensive as that of the other two family
members [36]. Furthermore, the simultaneous disruption
of both of the endogenous MBNL proteins in HeLa cells
by siRNA knockdown promotes NF1 exon 23a skipping
which is consistent with our hypothesis that they are
positive regulators and that they function redundantly in
this system.
The MBNL binding motif is located within the intronic
sequence upstream of NF1 exon 23a
Using bioinformatic techniques, a recent study revealed
that there is an enrichment of both MBNL and CELF
binding sites surrounding developmentally regulated al-
ternative exons, and that these sites are conserved in
chicken and mouse, as well as in several other mamma-
lian species [23]. It is possible that MBNL proteins en-
hance or silence the expression of their target alternative
exons in a location-dependent manner. In their study,
Kalsotra and coworkers found that the MBNL binding
motifs located within the last 250 bases of upstream
introns were significantly associated with exon skipping
in MBNL-expressing cells [23,32].
Our in vitro UV cross-linking experiments have shown
that recombinant MBNL proteins can bind to two
UGCUGU binding motifs located upstream of exon 23a,
suggesting that these binding motifs could be involved
in promoting exon 23a inclusion. This result is interesting
because it implies that the MBNL proteins can function
as positive regulators by binding to upstream UG-rich
sequences. As discussed above, MBNL binding sites
located in the intronic region upstream of an alternative
exon usually promote skipping of the alternative exon.
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cardiac troponin T (cTNT) pre-mRNA are located in the
intron upstream of exon 5, and consistent with the bio-
informatics data, MBNL proteins promote exon 5 skip-
ping [20]. Also, in the case of insulin receptor exon 11
regulation, the MBNL protein binding sites are located
downstream of exon 11 and MBNL proteins promote the
inclusion of this exon [20]. The functional significance of
the two UGCUGU motifs needs to be further investigated
using mutant minigenes to confirm that these sites indeed
function in the MBNL protein-mediated splicing regula-
tion of NF1 exon 23a.
Recombinant MBNL1 protein binds strongly to the
upstream-most wild-type RNA sequence, which contains
one of the potential MBNL1 binding sites, but as pre-
dicted, binding was lost when either the MBNL site
alone or both the MBNL and potential CELF binding
sites were abolished (Figure 5B, compare lanes 2, 4, and
6). Surprisingly, the recombinant MBNL1 protein could
not bind as strongly to the RNA sequence in which the
potential MBNL site was intact but other UG elements
were abolished (Figure 5B, compare lanes 2 and 8). This
result suggests that for optimal binding the MBNL pro-
teins require additional upstream UG sequences. In the
literature, a number of MBNL binding sites have been
identified in both pre-mRNA targets and in the CUG or
CCUG repeats associated with myotonic dystrophy
[20,37-42]. The common features of these binding sites
are that they are pyrimidine-rich themselves and are
usually surrounded by pyrimidine-rich sequences, and
they generally feature the YGCY (where Y is a pyrimi-
dine) motif [42]. While the two predicted MBNL binding
sites upstream of NF1 exon 23a fit the profile for con-
taining the YGCY motif (UGCUGU), the additional se-
quence that was abolished from upstream mutant 3 does
not have this motif (Figure 5A). However, the entire re-
gion upstream of this exon is pyrimidine-rich, which is
consistent with the current knowledge about other in-
tronic regions surrounding MBNL protein-regulated al-
ternative exons. It is interesting that switching only one
residue from a pyrimidine to a purine can have such a
profound effect on the binding of MBNL1 (Figure 5A,
compare upstream wild-type sequence with upstream
mutant 3 sequence). Perhaps this effect is so strong be-
cause the pyrimidine to purine change was made in such
close proximity to the predicted MBNL binding site. It is
also possible that this change could have disrupted an
RNA secondary structure or some other mechanism that
promotes optimal MBNL1 binding to the pre-mRNA. It
has been shown that MBNL proteins can regulate some
of their pre-mRNA targets by binding to the stem of
RNA stem-loop structures containing their binding sites
[40,41]. Using a structure prediction software program,
we found that stem-loop structures are predicted to formupstream of exon 23a, and that these structures involve the
two potential UGCUGU binding motifs (data not shown).
Furthermore, these predicted secondary structures are con-
served in humans, mice, and chickens. The role of the po-
tential secondary structure in MBNL-mediated inclusion of
NF1 exon 23a remains to be investigated.
NF1 exon 23a is antagonistically regulated by the MBNL
and CELF protein families
Our over-expression studies in CA77 and HeLa cells
have demonstrated that the levels of CELF and MBNL
proteins are important for determining whether NF1
exon 23a will be included or skipped, and these findings
are consistent with the hypothesis that CELF and MBNL
proteins act as antagonists in the regulation of this alter-
native splicing event. The identification of NF1 exon 23a
as a new target of CELF and MBNL protein antagonistic
splicing regulation is important, because NF1 has a crit-
ical role in the developing heart. It has been shown pre-
viously that mice deficient for Nf1 die at mid-gestation
due to heart development-related complications, and
that there is an important mesenchymal to endothelial
transition at this stage in mouse heart development for
which Nf1 is important [43]. NF1 exon 23a is located
within the GRD of the neurofibromin protein, and the
two NF1 isoforms differ in their abilities to negatively
control Ras signaling. Also this exon is under complex
control by at least four groups of regulatory proteins,
suggesting that its function is essential in the proper
management of Ras signaling in vivo. Thus, it is intri-
guing to hypothesize that NF1 signaling could be dis-
rupted in the hearts of DM1 patients since the inclusion
of NF1 exon 23a is antagonistically regulated by the
CELF and MBNL proteins.
In the known antagonistically regulated pre-mRNA
targets, CELF and MBNL proteins bind to distinct bind-
ing sequences. Ho and colleagues used minigene repor-
ters for cTNT exon 5 and insulin receptor exon 11 with
either MBNL or CELF sites disrupted to demonstrate
that neither protein needs the other protein’s site in
order to regulate the alternative exon [20]. Our in vitro
binding assays suggest that there may be some overlap
in binding sequences for the MBNL and CELF proteins
on the NF1 pre-mRNA. In Figure 5C, we show that re-
combinant CELF2 binds strongly to the upstream RNA
sequence, but its binding is reduced for all three
mutants (compare lanes 2, 4, 6, and 8). In addition, al-
though binding to the downstream sequence is not as
strong as to the upstream sequence, there is also a great
reduction in binding to the downstream MBNL site mu-
tant. Since the MBNL sites are UG-rich, it is not surpris-
ing that the recombinant CELF2 protein binds better
when there is more of that type of sequence available. In
our work, we have used two representative CELF
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CELF and MBNL proteins. Previous studies have shown
that CELF2 and CELF3 can behave differently in other
systems [44,45], but the two proteins function redun-
dantly for NF1 exon 23a [27] and therefore may be used
interchangeably in our experiments.
Conclusions
In summary, the study reported here adds NF1 exon 23a
to a short list of pre-mRNAs that are antagonistically
regulated by the CELF and MBNL protein families.
These studies also add an additional positive regulatory
factor to the list of proteins and regulatory mechanisms
that control the expression of NF1 exon 23a. These find-
ings are especially interesting because they suggest a
novel mechanism by which the MBNL and CELF pro-
teins can function antagonistically, since there may be
some overlap between their binding motifs as demon-
strated by our in vitro binding assays.
Methods
Plasmids
The human NF1 minigene reporter was previously
described [27,29]. The protein expression plasmids for
CELF3, MBNL1, MBNL2, MBNL3 and Y-Box protein
were gifts from Dr. Tom Cooper at Baylor College of
Medicine. The expression plasmid for hnRNP L was a
gift from Dr. Kristen Lynch at University of Pennsylvania.
Cell culture and cell transfections
HeLa and CA77 cells were cultured and transfected as
previously described [27,29]. HeLa cells were obtained
from American Type Culture Collection (Manassas, VA)
and CA77 cells, a cell line derived from rat medullary thy-
roid carcinoma (a gift from Dr. Andrew Russo, University
of Iowa, Iowa City, IA) [46,47].
RNA and protein analysis
The procedures for the isolation of total RNA and pro-
tein and for RT-PCR were performed as previously
described [27,29]. Western blot analysis to analyze
MBNL1 and CELF protein expression were carried out
using either 50 μg of total protein lysate from transfected
HeLa cells or 100 μg of total protein lysate from trans-
fected CA77 cells loaded onto 10% polyacrylamide gels.
Proteins were transferred to polyvinylidene fluoride
(PVDF) membranes at 4°C overnight at 40 Volts. Following
overnight transfer, the membranes were blocked in a
5% milk/PBST solution for one hour and then blotted
with Anti-Xpress antibody (Invitrogen) at a dilution of
1:2000 and Anti-U1 70K at a dilution of 1:250 as a
loading control for one hour. The membranes were
then washed three times for 5 min each in 1X PBST,
and then subjected to blotting with Goat Anti-Mousesecondary antibody (Pierce) at a dilution of 1:1250.
After three final washes in 1X PBST for 5 min each, the
HeLa cell blots were incubated with Pierce Pico HRP
substrate for 15 min and exposed to X-ray film. For
proteins derived from CA77 cell transfections, blots
were incubated for five minutes in Immobilon Western
Chemiluminescent HRP substrate (Millipore), and then
exposed to X-ray film.siRNA-mediated knockdown of MBNL1 and MBNL2
The siRNA duplexes were synthesized by Dharmacon
(Thermo Scientific). We used the Dharmacon MBNL2
SMARTpool siRNA, and the target sequence of the
MBNL1 siRNA is 50AACACGGAAUGUAAAUUUGC
A30 as previously described by Ho and colleagues [20].
For a negative control, we used siRNA against human
USP13, which is a deubiquitination enzyme, and its
target sequence is 50UGAUUGAGAUGGAGAAUAA30.
Co-transfections were performed in HeLa cells using a
total of 300 pmoles of either control siRNA as a negative
control, or 200 pmoles of MBNL1 siRNA plus 100 pmoles
of MBNL2 siRNA using DharmaFECT1 (Dharmacon).
RT-PCR was utilized to detect changes in endogenous
levels of MBNL1 and MBNL2 mRNA upon siRNA knock-
down and Beta Actin was used as a loading control. The
sequences for the RT-PCR oligonucleotides are: Beta Actin
(Sense: 50TGGGCGACGAGGCCCAGAGCA30 and Anti-
sense: 50GTCAGGTCCCGGCCAGCCAGG30); MBNL1
(Sense: 50ATGGCTGTTAGTGTCACACCA30 and Anti-
sense: 50CATGTTCTTCTGCTGAATCAA30); MBNL2
(Sense: 50CAGGTTGAAAATGGAAGAGTAA30 and Anti-
sense: 50TTGAGCCCGGGACAGTGACCGG30).
UV cross-linking assays
Recombinant GST and GST-CELF2 were prepared from
bacteria using the B-PER GST fusion protein purification
kit (Pierce/Thermo Scientific), and they were dialyzed
into Roeder D [48]. Recombinant GST-MBNL1 was pre-
pared as previously described [49], and then dialyzed
into Roeder D. RNA oligonucleotides were synthesized
commercially with a protective cap by Dharmacon/
Thermo Scientific. The RNA oligonucleotides were sub-
jected to a mild deprotection protocol prior to being
end-labeled with 32P-ATP. UV cross-linking assays
were carried out in a volume of 25 μL containing 2
mM ATP, 20 mM creatine phosphate, 0.6 mM MgCl2,
1.5% polyethylene glycol, 0.15 mM dithiothreitol, and
5 x 105 cpm of 32P-labeled RNA, and either 100 ng of
GST or GST-CELF2 or 750 ng GST or GST-MBNL1.
Reaction mixtures were incubated at 30°C for 30 min,
and heparin was added to a final concentration of 2
μg/μl, followed by UV irradiation (254 nm) at 4°C for
15 min. The cross-linked proteins were analyzed using
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phoresis gels.
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